Gene expression profiling of leukemia cells of primary T-ALL patients

T-cell acute lymphoblastic leukemia/lymphoma(T-ALL) is a malignancy curable in ~80% of pediatric and ~40% of adult patients. It is a heterogeneous disease characterized by the presence of leukemia stem cells(LSCs) which have been postulated to be responsible for relapses. To determine the immunophenotype that can reveal the LSC heterogeneity, we have performed a single cell RNA sequencing (scRNA-Seq) profiling, simultaneously with a panel of 42 oligo-conjugated antibodies against cell surface protein markers (AbSeq assay) in 3 primary samples of human T-ALLs at the diagnosis and minimal residual disease 30 days after the start of the therapy without any expansion into immunocompromised mice.